Discover
RNAM
Avidity Biosciences Inc
72.86
2 x 72.70
2 x 72.92
bid
ask
+
0.00
0.00%
11:42 AM
timesize
| Ytd | 1.01% | |
| 1y | 149.35% |
72.86
day range
72.86
21.51
52 week range
73.06
| Open | 72.86 | Prev Close | 72.86 | Low | 72.86 | High | 72.86 | Mkt Cap | 11.26B |
| Vol | 0.00 | Avg Vol | 2.70M | EPS | -4.19 | P/E | -17.39 | Forward P/E | N/A |
| Beta | 0.93 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 72.52 | 200-d Avg | 52.68 | 1yr Est | 0.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-02-23 | 2025-12 | -1.3 | -1.59 | -0.29 | -22.56% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|